APO Research
Talk to an analyst

APO RESEARCH · REPORT

Coronavirus Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Coronavirus Treatment Drugs Market Outlook and Growth Opportunities 2026

20 December 2025201 pages

Choose your research edition.

Industry ResearchCoronavirus Treatment Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Coronavirus Treatment Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Coronavirus Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coronavirus Treatment Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Coronavirus Treatment Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Coronavirus Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Coronavirus Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Coronavirus Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Coronavirus Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Coronavirus Treatment Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Coronavirus Treatment Drugs market include Bharat Biotech International Limited, Cadila Healthcare Limited, CanSino Biologics, Celltrion Healthcare, Dr. Reddy's Laboratories, Gilead Sciences, Glenmark Pharmaceuticals Limited, Moderna and Novavax, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Coronavirus Treatment Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Coronavirus Treatment Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Coronavirus Treatment Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Coronavirus Treatment Drugs market.

Coronavirus Treatment Drugs Segment by Company

Bharat Biotech International Limited

Cadila Healthcare Limited

CanSino Biologics

Celltrion Healthcare

Dr. Reddy's Laboratories

Gilead Sciences

Glenmark Pharmaceuticals Limited

Moderna

Novavax, Inc

Serum Institute of India

Sinovac Biotech

Sorrento Therapeutics

AstraZeneca Plc

GlaxoSmithKline Plc

Pfizer Inc

Eli Lilly and Company

Roche

Merck & Co., Inc

Johnson & Johnson

Coronavirus Treatment Drugs Segment by Type

Monoclonal Antibodies

Kinase Inhibitors

Anti-viral

Corticosteroids

Others

Coronavirus Treatment Drugs Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Coronavirus Treatment Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Coronavirus Treatment Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Coronavirus Treatment Drugs key companies, revenue, market share, and recent developments.

3. To split the Coronavirus Treatment Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Coronavirus Treatment Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Coronavirus Treatment Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Coronavirus Treatment Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coronavirus Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coronavirus Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coronavirus Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Coronavirus Treatment Drugs industry.

Chapter 3: Detailed analysis of Coronavirus Treatment Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Coronavirus Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Coronavirus Treatment Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Coronavirus Treatment Drugs Industry Trends Table 2. Coronavirus Treatment Drugs Industry Drivers Table 3. Coronavirus Treatment Drugs Industry Opportunities and Challenges Table 4. Coronavirus Treatment Drugs Industry Restraints Table 5. Global Coronavirus Treatment Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Coronavirus Treatment Drugs Revenue Share by Company (2021-2026) Table 7. Global Coronavirus Treatment Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Coronavirus Treatment Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Coronavirus Treatment Drugs Company, Product Type & Application Table 10. Global Coronavirus Treatment Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Coronavirus Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Antibodies Table 15. Significant Companies of Kinase Inhibitors Table 16. Significant Companies of Anti-viral Table 17. Significant Companies of Corticosteroids Table 18. Significant Companies of Others Table 19. Global Coronavirus Treatment Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Coronavirus Treatment Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Coronavirus Treatment Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Coronavirus Treatment Drugs Sales Value Share by Type (2021-2026) Table 23. Global Coronavirus Treatment Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Hospital Pharmacies Table 27. Global Coronavirus Treatment Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Coronavirus Treatment Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Coronavirus Treatment Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Coronavirus Treatment Drugs Sales Value Share by Application (2021-2026) Table 31. Global Coronavirus Treatment Drugs Sales Value Share by Application (2027-2032) Table 32. Global Coronavirus Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Coronavirus Treatment Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Coronavirus Treatment Drugs Sales Value Share by Region (2021-2026) Table 35. Global Coronavirus Treatment Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Coronavirus Treatment Drugs Sales Value Share by Region (2027-2032) Table 37. Global Coronavirus Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Coronavirus Treatment Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Coronavirus Treatment Drugs Sales Value Market Share by Country (2021-2026) Table 40. Global Coronavirus Treatment Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Coronavirus Treatment Drugs Sales Value Market Share by Country (2027-2032) Table 42. Bharat Biotech International Limited Company Information Table 43. Bharat Biotech International Limited Business Overview Table 44. Bharat Biotech International Limited Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Bharat Biotech International Limited Coronavirus Treatment Drugs Product Portfolio Table 46. Bharat Biotech International Limited Recent Development Table 47. Cadila Healthcare Limited Company Information Table 48. Cadila Healthcare Limited Business Overview Table 49. Cadila Healthcare Limited Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Cadila Healthcare Limited Coronavirus Treatment Drugs Product Portfolio Table 51. Cadila Healthcare Limited Recent Development Table 52. CanSino Biologics Company Information Table 53. CanSino Biologics Business Overview Table 54. CanSino Biologics Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. CanSino Biologics Coronavirus Treatment Drugs Product Portfolio Table 56. CanSino Biologics Recent Development Table 57. Celltrion Healthcare Company Information Table 58. Celltrion Healthcare Business Overview Table 59. Celltrion Healthcare Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Celltrion Healthcare Coronavirus Treatment Drugs Product Portfolio Table 61. Celltrion Healthcare Recent Development Table 62. Dr. Reddy's Laboratories Company Information Table 63. Dr. Reddy's Laboratories Business Overview Table 64. Dr. Reddy's Laboratories Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Dr. Reddy's Laboratories Coronavirus Treatment Drugs Product Portfolio Table 66. Dr. Reddy's Laboratories Recent Development Table 67. Gilead Sciences Company Information Table 68. Gilead Sciences Business Overview Table 69. Gilead Sciences Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Gilead Sciences Coronavirus Treatment Drugs Product Portfolio Table 71. Gilead Sciences Recent Development Table 72. Glenmark Pharmaceuticals Limited Company Information Table 73. Glenmark Pharmaceuticals Limited Business Overview Table 74. Glenmark Pharmaceuticals Limited Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Glenmark Pharmaceuticals Limited Coronavirus Treatment Drugs Product Portfolio Table 76. Glenmark Pharmaceuticals Limited Recent Development Table 77. Moderna Company Information Table 78. Moderna Business Overview Table 79. Moderna Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Moderna Coronavirus Treatment Drugs Product Portfolio Table 81. Moderna Recent Development Table 82. Novavax, Inc Company Information Table 83. Novavax, Inc Business Overview Table 84. Novavax, Inc Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novavax, Inc Coronavirus Treatment Drugs Product Portfolio Table 86. Novavax, Inc Recent Development Table 87. Serum Institute of India Company Information Table 88. Serum Institute of India Business Overview Table 89. Serum Institute of India Coronavirus Treatment Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Serum Institute of India Coronavirus Treatment Drugs Product Portfolio Table 91. Serum Institute of India Recent Development Table 92. Sinovac Biotech Company Information Table 93. Sinovac Biotech Business Overview Table 94. Sinovac Biotech Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sinovac Biotech Coronavirus Treatment Drugs Product Portfolio Table 96. Sinovac Biotech Recent Development Table 97. Sorrento Therapeutics Company Information Table 98. Sorrento Therapeutics Business Overview Table 99. Sorrento Therapeutics Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sorrento Therapeutics Coronavirus Treatment Drugs Product Portfolio Table 101. Sorrento Therapeutics Recent Development Table 102. AstraZeneca Plc Company Information Table 103. AstraZeneca Plc Business Overview Table 104. AstraZeneca Plc Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Plc Coronavirus Treatment Drugs Product Portfolio Table 106. AstraZeneca Plc Recent Development Table 107. GlaxoSmithKline Plc Company Information Table 108. GlaxoSmithKline Plc Business Overview Table 109. GlaxoSmithKline Plc Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline Plc Coronavirus Treatment Drugs Product Portfolio Table 111. GlaxoSmithKline Plc Recent Development Table 112. Pfizer Inc Company Information Table 113. Pfizer Inc Business Overview Table 114. Pfizer Inc Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Pfizer Inc Coronavirus Treatment Drugs Product Portfolio Table 116. Pfizer Inc Recent Development Table 117. Eli Lilly and Company Company Information Table 118. Eli Lilly and Company Business Overview Table 119. Eli Lilly and Company Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Eli Lilly and Company Coronavirus Treatment Drugs Product Portfolio Table 121. Eli Lilly and Company Recent Development Table 122. Roche Company Information Table 123. Roche Business Overview Table 124. Roche Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Roche Coronavirus Treatment Drugs Product Portfolio Table 126. Roche Recent Development Table 127. Merck & Co., Inc Company Information Table 128. Merck & Co., Inc Business Overview Table 129. Merck & Co., Inc Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Merck & Co., Inc Coronavirus Treatment Drugs Product Portfolio Table 131. Merck & Co., Inc Recent Development Table 132. Johnson & Johnson Company Information Table 133. Johnson & Johnson Business Overview Table 134. Johnson & Johnson Coronavirus Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Johnson & Johnson Coronavirus Treatment Drugs Product Portfolio Table 136. Johnson & Johnson Recent Development Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Coronavirus Treatment Drugs Product Image Figure 2. Global Coronavirus Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coronavirus Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Coronavirus Treatment Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Antibodies Image Figure 8. Kinase Inhibitors Image Figure 9. Anti-viral Image Figure 10. Corticosteroids Image Figure 11. Others Image Figure 12. Global Coronavirus Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Coronavirus Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Coronavirus Treatment Drugs Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Hospital Pharmacies Image Figure 18. Global Coronavirus Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Coronavirus Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Coronavirus Treatment Drugs Sales Value Share by Application (2021-2032) Figure 21. Global Coronavirus Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Coronavirus Treatment Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Coronavirus Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. North America Coronavirus Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Coronavirus Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Coronavirus Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Coronavirus Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Coronavirus Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Coronavirus Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. South America Coronavirus Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Coronavirus Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Coronavirus Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Kinase Inhibitors
  • Anti-viral
  • Corticosteroids
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Bharat Biotech International Limited
  • Cadila Healthcare Limited
  • CanSino Biologics
  • Celltrion Healthcare
  • Dr. Reddy's Laboratories
  • Gilead Sciences
  • Glenmark Pharmaceuticals Limited
  • Moderna
  • Novavax, Inc
  • Serum Institute of India
  • Sinovac Biotech
  • Sorrento Therapeutics
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Eli Lilly and Company
  • Roche
  • Merck & Co., Inc
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Coronavirus Treatment Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Coronavirus Treatment Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Coronavirus Treatment Drugs Market Dynamics
  1. 2.1 Coronavirus Treatment Drugs Industry Trends
  2. 2.2 Coronavirus Treatment Drugs Industry Drivers
  3. 2.3 Coronavirus Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Coronavirus Treatment Drugs Industry Restraints
3 Coronavirus Treatment Drugs Market by Company
  1. 3.1 Global Coronavirus Treatment Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Coronavirus Treatment Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Coronavirus Treatment Drugs Company Ranking (2024-2026)
  4. 3.4 Global Coronavirus Treatment Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Coronavirus Treatment Drugs Company Product Type and Application
  6. 3.6 Global Coronavirus Treatment Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Coronavirus Treatment Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Coronavirus Treatment Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Coronavirus Treatment Drugs Market by Type
  1. 4.1 Coronavirus Treatment Drugs Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Kinase Inhibitors
  4. 4.1.3 Anti-viral
  5. 4.1.4 Corticosteroids
  6. 4.1.5 Others
  7. 4.2 Global Coronavirus Treatment Drugs Sales Value by Type
  8. 4.2.1 Global Coronavirus Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Coronavirus Treatment Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Coronavirus Treatment Drugs Sales Value Share by Type (2021-2032)
5 Coronavirus Treatment Drugs Market by Application
  1. 5.1 Coronavirus Treatment Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Coronavirus Treatment Drugs Sales Value by Application
  6. 5.2.1 Global Coronavirus Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Coronavirus Treatment Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Coronavirus Treatment Drugs Sales Value Share by Application (2021-2032)
6 Coronavirus Treatment Drugs Regional Value Analysis
  1. 6.1 Global Coronavirus Treatment Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Coronavirus Treatment Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Coronavirus Treatment Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Coronavirus Treatment Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Coronavirus Treatment Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Coronavirus Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Coronavirus Treatment Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Coronavirus Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Coronavirus Treatment Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Coronavirus Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Coronavirus Treatment Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Coronavirus Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Coronavirus Treatment Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Coronavirus Treatment Drugs Sales Value Share by Country, 2025 VS 2032
7 Coronavirus Treatment Drugs Country-level Value Analysis
  1. 7.1 Global Coronavirus Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Coronavirus Treatment Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Coronavirus Treatment Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Coronavirus Treatment Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Coronavirus Treatment Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Coronavirus Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Coronavirus Treatment Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bharat Biotech International Limited
  2. 8.1.1 Bharat Biotech International Limited Company Information
  3. 8.1.2 Bharat Biotech International Limited Business Overview
  4. 8.1.3 Bharat Biotech International Limited Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bharat Biotech International Limited Coronavirus Treatment Drugs Product Portfolio
  6. 8.1.5 Bharat Biotech International Limited Recent Developments
  7. 8.2 Cadila Healthcare Limited
  8. 8.2.1 Cadila Healthcare Limited Company Information
  9. 8.2.2 Cadila Healthcare Limited Business Overview
  10. 8.2.3 Cadila Healthcare Limited Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cadila Healthcare Limited Coronavirus Treatment Drugs Product Portfolio
  12. 8.2.5 Cadila Healthcare Limited Recent Developments
  13. 8.3 CanSino Biologics
  14. 8.3.1 CanSino Biologics Company Information
  15. 8.3.2 CanSino Biologics Business Overview
  16. 8.3.3 CanSino Biologics Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CanSino Biologics Coronavirus Treatment Drugs Product Portfolio
  18. 8.3.5 CanSino Biologics Recent Developments
  19. 8.4 Celltrion Healthcare
  20. 8.4.1 Celltrion Healthcare Company Information
  21. 8.4.2 Celltrion Healthcare Business Overview
  22. 8.4.3 Celltrion Healthcare Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celltrion Healthcare Coronavirus Treatment Drugs Product Portfolio
  24. 8.4.5 Celltrion Healthcare Recent Developments
  25. 8.5 Dr. Reddy's Laboratories
  26. 8.5.1 Dr. Reddy's Laboratories Company Information
  27. 8.5.2 Dr. Reddy's Laboratories Business Overview
  28. 8.5.3 Dr. Reddy's Laboratories Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr. Reddy's Laboratories Coronavirus Treatment Drugs Product Portfolio
  30. 8.5.5 Dr. Reddy's Laboratories Recent Developments
  31. 8.6 Gilead Sciences
  32. 8.6.1 Gilead Sciences Company Information
  33. 8.6.2 Gilead Sciences Business Overview
  34. 8.6.3 Gilead Sciences Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead Sciences Coronavirus Treatment Drugs Product Portfolio
  36. 8.6.5 Gilead Sciences Recent Developments
  37. 8.7 Glenmark Pharmaceuticals Limited
  38. 8.7.1 Glenmark Pharmaceuticals Limited Company Information
  39. 8.7.2 Glenmark Pharmaceuticals Limited Business Overview
  40. 8.7.3 Glenmark Pharmaceuticals Limited Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark Pharmaceuticals Limited Coronavirus Treatment Drugs Product Portfolio
  42. 8.7.5 Glenmark Pharmaceuticals Limited Recent Developments
  43. 8.8 Moderna
  44. 8.8.1 Moderna Company Information
  45. 8.8.2 Moderna Business Overview
  46. 8.8.3 Moderna Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Moderna Coronavirus Treatment Drugs Product Portfolio
  48. 8.8.5 Moderna Recent Developments
  49. 8.9 Novavax, Inc
  50. 8.9.1 Novavax, Inc Company Information
  51. 8.9.2 Novavax, Inc Business Overview
  52. 8.9.3 Novavax, Inc Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novavax, Inc Coronavirus Treatment Drugs Product Portfolio
  54. 8.9.5 Novavax, Inc Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Coronavirus Treatment Drugs Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 Sinovac Biotech
  62. 8.11.1 Sinovac Biotech Company Information
  63. 8.11.2 Sinovac Biotech Business Overview
  64. 8.11.3 Sinovac Biotech Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sinovac Biotech Coronavirus Treatment Drugs Product Portfolio
  66. 8.11.5 Sinovac Biotech Recent Developments
  67. 8.12 Sorrento Therapeutics
  68. 8.12.1 Sorrento Therapeutics Company Information
  69. 8.12.2 Sorrento Therapeutics Business Overview
  70. 8.12.3 Sorrento Therapeutics Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sorrento Therapeutics Coronavirus Treatment Drugs Product Portfolio
  72. 8.12.5 Sorrento Therapeutics Recent Developments
  73. 8.13 AstraZeneca Plc
  74. 8.13.1 AstraZeneca Plc Company Information
  75. 8.13.2 AstraZeneca Plc Business Overview
  76. 8.13.3 AstraZeneca Plc Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Plc Coronavirus Treatment Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Plc Recent Developments
  79. 8.14 GlaxoSmithKline Plc
  80. 8.14.1 GlaxoSmithKline Plc Company Information
  81. 8.14.2 GlaxoSmithKline Plc Business Overview
  82. 8.14.3 GlaxoSmithKline Plc Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline Plc Coronavirus Treatment Drugs Product Portfolio
  84. 8.14.5 GlaxoSmithKline Plc Recent Developments
  85. 8.15 Pfizer Inc
  86. 8.15.1 Pfizer Inc Company Information
  87. 8.15.2 Pfizer Inc Business Overview
  88. 8.15.3 Pfizer Inc Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Pfizer Inc Coronavirus Treatment Drugs Product Portfolio
  90. 8.15.5 Pfizer Inc Recent Developments
  91. 8.16 Eli Lilly and Company
  92. 8.16.1 Eli Lilly and Company Company Information
  93. 8.16.2 Eli Lilly and Company Business Overview
  94. 8.16.3 Eli Lilly and Company Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Eli Lilly and Company Coronavirus Treatment Drugs Product Portfolio
  96. 8.16.5 Eli Lilly and Company Recent Developments
  97. 8.17 Roche
  98. 8.17.1 Roche Company Information
  99. 8.17.2 Roche Business Overview
  100. 8.17.3 Roche Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Roche Coronavirus Treatment Drugs Product Portfolio
  102. 8.17.5 Roche Recent Developments
  103. 8.18 Merck & Co., Inc
  104. 8.18.1 Merck & Co., Inc Company Information
  105. 8.18.2 Merck & Co., Inc Business Overview
  106. 8.18.3 Merck & Co., Inc Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Merck & Co., Inc Coronavirus Treatment Drugs Product Portfolio
  108. 8.18.5 Merck & Co., Inc Recent Developments
  109. 8.19 Johnson & Johnson
  110. 8.19.1 Johnson & Johnson Company Information
  111. 8.19.2 Johnson & Johnson Business Overview
  112. 8.19.3 Johnson & Johnson Coronavirus Treatment Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Johnson & Johnson Coronavirus Treatment Drugs Product Portfolio
  114. 8.19.5 Johnson & Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst